Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levetiracetam versus oxcarbazepine monotherapy in newly or recently diagnosed partial epilepsy
2014-002713-32Phase 4
- Sponsor
- UCB Korea
- Start
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in epilepsy comparing Keppra monotherapy with Trileptal monotherapy (2 arms). Primary endpoint: Treatment failure rate at 50 weeks.
02
Drugs
levetiracetamoxcarbazepine
03
Conditions
epilepsy
Beyond the preview
Go deeper on 2014-002713-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002713-32.